Core Viewpoint - The company held a Q3 2025 earnings presentation on November 19, 2025, to discuss its financial status, market expansion, R&D projects, and future strategies with investors [1][2]. Group 1: Earnings Presentation Overview - The earnings presentation was conducted via the Shanghai Stock Exchange's online platform, with key executives including the chairman and CFO in attendance [2]. - The company disclosed its Q3 2025 report on October 29, 2025, prior to the earnings presentation [1]. Group 2: Investor Questions and Company Responses - The company is focusing on expanding its sales channels to include outpatient markets and grassroots medical institutions, aiming to integrate resources across different healthcare settings [3]. - The market demand for steroid hormones and amino acids is competitive, prompting the company to concentrate on core areas such as dermatology and respiratory health while enhancing its product pipeline [3]. - The company anticipates challenges in achieving its 2025 annual performance targets due to price reductions from centralized procurement and intensified competition, but it plans to adapt its sales strategies and enhance market operations [3]. - Recent product developments include two products passing the consistency evaluation for generic drug quality and efficacy, and several products receiving registration certificates [4]. - The company reported that the market prospects for butorphanol tartrate injection are promising, with projected sales of CNY 1.965 billion in 2023 and CNY 1.899 billion in 2024 [4]. - The company emphasizes its commitment to returning value to investors, maintaining a cash dividend ratio exceeding 80% since 2023, and focusing on sustainable growth [4]. - The company is enhancing its compliance management systems and conducting regular training to foster a strong compliance culture [4].

证券代码：600488 证券简称：津药药业 编号：2025-068 津药药业股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司对投资者在本次说明会上主要关注的问题进行了回复，具体 情况如下： 1 / 4 1.针对终端用药量减少的市场情况，公司是否计划拓展院外市场、 基层医疗等新渠道，目前在渠道建设上有哪些进展？ 投资者您好，公司在全国药品流通领域构建了成熟且稳定的销售 渠道，产品主要销往医院、零售药店和基层医疗机构等不同终端。在 新的商业环境下，公司致力于打通医疗零售等院内外渠道，并实现资 源的协同整合。感谢您的关注！ 津药药业股份有限公司（以下简称"公司"）于2025年11月19 日 14:00-15:00 ， 通 过 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/）采用网络互动方式召开了2025 年第三季度业绩说明会，现将活动情况公告如下： 一、说明会召开的情况 公司于2025年10月2 ...

Group 1 - The company’s subsidiary, Tianjin Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable drug, Methylprednisolone Sodium Succinate, allowing it to produce and sell the product in the Panamanian market [1][2] - The drug is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases and tumors, and shock treatment [1] - The global market sales for Methylprednisolone injectable products were reported to be $526 million in 2023 and $521 million in 2024 according to the IQVIA database [1] Group 2 - The registration of the drug is expected to create new opportunities for the company’s formulation business in the Panamanian market and further promote its international strategic layout [2] - The timeline for the drug's sales in foreign markets, market size, and subsequent expansion progress remains uncertain, influenced by external market conditions and exchange rate fluctuations [2]

Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate, allowing the company to produce and sell the product in the Panamanian market [1] Group 1 - The product is an injectable form of methylprednisolone sodium succinate [1] - The registration certification signifies a key milestone for the company in expanding its market presence in Panama [1] - This development may enhance the company's revenue potential through new market opportunities [1]

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

获得巴拿马共和国卫生部注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600488 证券简称：津药药业 编号：2025-067 津药药业股份有限公司 关于子公司注射用甲泼尼龙琥珀酸钠 津药和平注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书， 将为制剂业务拓展巴拿马市场带来新机遇，也将进一步推动公司国际化战略 布局。由于该药品在国外市场销售的时间、市场规模、后续拓展进度具有不 确定性，加之药品出口业务容易受到国外市场环境变化、汇率波动等因素影 1 / 2 2.剂型：注射用冻干粉针剂 3.规格：500mg 4.持有人：津药和平（天津）制药有限公司 5.批准文号：210124 6.发证机构：巴拿马共和国卫生部 响，敬请广大投资者理性投资，注意防范投资风险。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天 津）制药有限公司（以下简称"津药和平"） 注射用甲泼尼龙琥珀酸钠（以 下简称"该药品"）获得巴拿马共和国卫生部注册证书（标志着可以生产并 在巴拿马共和国市场销售该产品），现将相 ...

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Acetate, allowing production and sales in the Panamanian market [1] Group 1 - The drug Methylprednisolone Acetate is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumors, and shock [1] - The registration application was submitted in 2024, and the certificate was received in November 2025 [1] - According to IQVIA data, the global market sales for Methylprednisolone injectable products were $526 million in 2023 and are projected to be $521 million in 2024 [1] Group 2 - The registration of Methylprednisolone Acetate in Panama presents new opportunities for the company's formulation business and further supports its international strategic layout [1]

津药药业（600488）(600488.SH)公告，公司子公司津药和平(天津)制药有限公司(简称"津药和平")注射 用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书(标志着可以生产并在巴拿马共和国市场销售该 产品)。注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治疗、血液 疾病和肿瘤的治疗、休克的治疗等。 ...

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. (600488.SH) announced that its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd., has received registration certification from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Sodium Succinate, allowing the product to be produced and sold in the Panamanian market [1] Group 1 - The injectable Methylprednisolone Sodium Succinate is a corticosteroid medication primarily used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumor treatment, and shock treatment [1]